Life Science Executive and FSHD Advocate/Father Shares his Knowledge and Experience

FSHD: Keeping the Patient Voice at the Center of Progress

Facioscapulohumeral muscular dystrophy, or FSHD, is often described as a progressive muscle disease affecting the face, shoulders, arms, trunk, and legs. That is accurate, but incomplete, because FSHD can affect muscles throughout the body. For people living with FSHD and the families who love them, the disease is far more than muscle weakness. It touches independence, identity, work, connection, emotional well-being, and daily routines many take for granted.

I write about FSHD not only as Dr. Raymond A. Huml, a healthcare executive, researcher, author, and advocate in rare disease and drug development, but also as a father. Two of my children live with FSHD. That reality has shaped how I think about science, clinical development, advocacy, and hope. It has also made clear that progress must be measured not only by what can be quantified in a clinic, but by what improves daily life.

FSHD is highly variable. Some people experience early, obvious functional changes; others progress slowly or unpredictably. Fatigue, pain, mobility loss, and difficulty with everyday tasks often come with uncertainty about the future. That uncertainty can affect education, careers, relationships, finances, and family life. For many, the burden is physical, emotional, and social.

Today, the therapeutic landscape is entering a new era. There is still no cure for FSHD and no approved disease-modifying treatment, so current care focuses on symptom management, function, mobility, and quality of life. At the same time, advances in DUX4 biology have moved research closer to targeted approaches, with more than 20 companies, universities, and research groups working on potential treatments. This momentum matters. But as science accelerates, the patient voice must remain central. Endpoints, biomarkers, imaging, and functional assessments are essential, yet they may not capture what patients and families most urgently want: less fatigue and pain, greater independence, more predictable function, and fuller participation in life.

My daughter and I helped start the North Carolina Chapter of the FSHD Society because we believed connection could become a form of strength. Community gives families information, encouragement, and a place to be understood. It also gives researchers, clinicians, industry leaders, and advocates a clearer view of living with FSHD. In rare disease, collaboration is not optional; it is the engine of progress.

On June 27, 2026, I will have the honor of giving the keynote address at FSHD Connect in Chicago. The theme of connection is especially meaningful because the meeting brings together the people who must shape the future: patients, families, researchers, clinicians, industry partners, and advocates. Each group sees a different part of the journey. Together, we can see enough of the whole picture to move wisely and urgently.

For drug developers, this is a critical moment. Innovation must be rigorous, but it must also be human. Treatment convenience, meaningful functional benefit, safety, access, and preservation of independence should all help define success. Listening to patients early and continuously can help ensure that new therapies address outcomes that matter in the real world, not only in controlled settings.

The future of FSHD is being built now. It will require science, investment, persistence, and trust; families willing to share their stories; and professionals willing to listen. As a father, advocate, and member of this community, I believe our responsibility is clear: keep patients at the center, keep collaboration strong, and keep pushing toward a future in which FSHD no longer defines what is possible.